TetraLogic Announces Licensing and Research Collaboration With Walter and Eliza Hall Institute of Medical Research
January 21 2014 - 7:30AM
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today
announced that it has entered into a research collaboration with
the Walter and Eliza Hall Institute of Medical Research to examine
TetraLogic's SMAC-Mimetic birinapant in viral infections.
Preclinical studies performed at the WEHI have indicated that
SMAC-Mimetics decrease the viral burden in mice with human
Hepatitis B Virus (HBV) by inducing apoptosis of virally infected
hepatocytes while sparing the non-infected cells.
TetraLogic has entered into a license agreement with WEHI for
worldwide exclusive rights to a patent application filed by the
institute relating to a method of treating intracellular infections
involving the administration of an Inhibitor of Apoptosis (IAP)
antagonist.
"Our work with TetraLogic, if successful, will provide a truly
novel approach," said Professor Douglas Hilton, Director, WEHI.
"This is further evidence of our commitment to perform research
that has a direct impact on the lives of patients."
"We are very excited about this collaboration and look forward
to further progress in the research program with WEHI," said Mr.
Kevin Buchi, CEO of TetraLogic. "This is an opportunity to
build on pioneering basic research to attack infectious disease
with a completely novel therapeutic approach."
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About the Walter and Eliza Hall Institute
WEHI is Australia's oldest medical research institute. It is
home to almost 750 researchers who are working to understand,
prevent and treat diseases including infectious diseases, cancers
and immune disorders. It is located in Parkville, Melbourne,
and is closely associated with The University of Melbourne and The
Royal Melbourne Hospital.
About TetraLogic
Tetralogic is a clinical-stage biopharmaceutical company focused
on discovering and developing novel small molecule therapeutics
that mimic Second Mitochondrial Activator of Caspases, or
SMAC-mimetics, and are designed to cause or enable abnormal cells
that are resistant to the body's immune system to self-destruct.
Birinapant, our clinical-stage product candidate, is
currently being tested in Phase 1 and Phase 2 oncology clinical
trials for hematological malignancies and multiple solid
tumors.
Forward Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. These statements relate to future
events or TetraLogic's pre-clinical and clinical development of
birinapant and other clinical programs, future expectations, plans
and prospects. Although TetraLogic believes that the
expectations reflected in such forward-looking statements are
reasonable as of the date made, expectations may prove to have been
materially different from the results expressed or implied by such
forward-looking statements. TetraLogic has attempted to
identify forward-looking statements by terminology including
''believes,'' ''estimates,'' ''anticipates,'' ''expects,''
''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,''
''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or
other words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. These statements
are only predictions and involve known and unknown risks,
uncertainties, and other factors, including those discussed under
the heading "Risk Factors" in our Registration Statement on Form
S-1 originally filed with the Securities and Exchange Commission on
October 18, 2013, as amended (Registration No. 333-191811).
Any forward-looking statements contained in this release speak
only as of its date. We undertake no obligation to update any
forward-looking statements contained in this release to reflect
events or circumstances occurring after its date or to reflect the
occurrence of unanticipated events.
CONTACT: Company Contact:
Pete A. Meyers
Chief Financial Officer and Treasurer
TetraLogic Pharmaceuticals Corporation
(610) 889-9900
pete.meyers@tlog.com
Investor Relations Contact:
Ami Bavishi
Burns McClellan, Inc.
(212) 213-0006
abavishi@burnsmc.com
TetraLogic Pharmaceuticals (CE) (USOTC:TLOG)
Historical Stock Chart
From Jun 2024 to Jul 2024
TetraLogic Pharmaceuticals (CE) (USOTC:TLOG)
Historical Stock Chart
From Jul 2023 to Jul 2024